AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · IEX Real-Time Price · USD

3.920

-0.130 (-3.21%)

At close: Apr 17, 2024, 4:00 PM

4.000

+0.080 (2.04%)

After-hours: Apr 17, 2024, 7:55 PM EDT

AbCellera Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	38.03	485.42	375.2	233.16	11.61	8.83
Revenue Growth (YoY)	-92.17%	29.38%	60.92%	1907.88%	31.49%	-
Gross Profit	38.03	485.42	375.2	233.16	11.61	8.83
Selling, General & Admin	75.18	66.76	48.76	15.75	4.01	2.86
Research & Development	175.66	107.88	62.06	29.39	10.11	5.8
Other Operating Expenses	24.4	94.28	59.97	31.98	1.6	0.92
Operating Expenses	275.23	268.91	170.79	77.12	15.73	9.58
Operating Income	-237.21	216.51	204.41	156.03	-4.12	-0.75
Interest Expense / Income	0	0	0	6.81	0.21	0.21
Other Expense / Income	-63.18	-22.59	-14.74	-8.61	-2.12	-1.27
Pretax Income	-174.03	239.1	219.15	157.83	-2.21	0.31
Income Tax	-27.63	80.58	65.69	38.92	0	0
Net Income	-146.4	158.52	153.46	118.92	-2.21	0.31
Net Income Growth	-	3.29%	29.05%	-	-	-
Shares Outstanding (Basic)	289	285	276	159	151	149
Shares Outstanding (Diluted)	289	315	318	263	151	171
Shares Change	-8.15%	-1.09%	20.96%	73.88%	-11.68%	-
EPS (Basic)	-0.51	0.56	0.56	0.53	-0.01	-
EPS (Diluted)	-0.51	0.50	0.48	0.45	-0.01	-
EPS Growth	-	4.17%	6.67%	-	-	-
Free Cash Flow	-120.82	206.7	186.13	13.02	-1.3	-1.74
Free Cash Flow Per Share	-0.42	0.72	0.68	0.08	-0.01	-0.01
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-623.82%	44.60%	54.48%	66.92%	-35.45%	-8.53%
Profit Margin	-385.00%	32.66%	40.90%	51.00%	-19.04%	3.50%
Free Cash Flow Margin	-317.75%	42.58%	49.61%	5.58%	-11.22%	-19.73%
Effective Tax Rate	-	33.70%	29.97%	24.66%	-	-
EBITDA	-143.14	272.2	236.4	169.92	-0.16	1.44
EBITDA Margin	-376.42%	56.07%	63.01%	72.88%	-1.33%	16.29%
Depreciation & Amortization	30.89	33.1	17.25	5.27	1.85	0.92
EBIT	-174.03	239.1	219.15	164.64	-2	0.52
EBIT Margin	-457.67%	49.26%	58.41%	70.62%	-17.24%	5.90%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).